Pharma Explained cover art

Pharma Explained

Pharma Explained

By: Pharma Now
Listen for free

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary

Pharma moves fast. Prices get capped, factories get inspected, a new injection gets a nod from a regulator on the other side of the world. And somewhere in all of that is a person picking up a strip of medicine at the chemist's counter.

Pharma Explained by Pharma Now, is your morning briefing on what's changing in pharma and life sciences, in about six minutes. Every episode picks one story that matters, tells you what happened, how it actually works, and what it means for the person who takes the medicine. India first, with the world in the frame.

Pharma Now
Episodes
  • Should One Failed Test Be Enough to Shut Down a Drug Factory?
    Nov 18 2026

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

    In this episode of Pharma Explained, by Pharma Now, we look at a draft rule from India’s Health Ministry that would suspend a drug factory’s licence the moment its medicine fails one of five key quality tests. Today, a failed lab report leads to a notice, a reply and a wait, and the medicine can stay on shelves in the meantime. We explain what the draft says, why the ministry wants to change this, and why some may worry about acting on a single lab result. We also look at why the solvents used in syrups are getting a paperwork trail of their own.

    We’ll cover:

    • How the current process works after a medicine fails a test.
    • What the draft rule would change.
    • Why supporters and critics see it differently.
    • What it could mean for patients, and what we still don’t know.
    • Why solvents used in syrups are getting extra checks.

    For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.

    Follow Pharma Now’s social handles:

    • LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/pharma-now/?viewAsMember=true⁠⁠⁠
    • Facebook: ⁠⁠⁠https://www.facebook.com/profile.php?id=61559659700692⁠⁠⁠
    • X: ⁠⁠⁠https://x.com/PharmaNowGlobal⁠⁠⁠
    • Instagram: ⁠⁠⁠https://www.instagram.com/pharmanow.live/⁠⁠⁠

    Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.

    Show More Show Less
    6 mins
  • Can India’s First Homegrown Antibiotic Help Beat Superbugs?
    Nov 18 2026

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

    In this episode of Pharma Explained, by Pharma Now, we look at an antibiotic that, according to its maker Wockhardt, is the first new medicine fully discovered and developed by an Indian company to be approved by the US FDA. It is designed for serious infections caused by bacteria that resist many existing antibiotics, a growing problem known as antimicrobial resistance. We explain how the medicine works, what its trial showed, and why one new antibiotic does not solve the bigger problem. We also look at who pays for the next generation of antibiotics, as World AMR Awareness Week continues.

    We’ll cover:

    • Why antibiotics are losing their power against some infections.
    • How the new medicine fights bacteria in two ways at once.
    • What the trial showed, and what it has not yet shown.
    • What it could mean for patients, and what we still don’t know, including price and Indian launch.
    • Why new antibiotics are hard to fund.

    For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.

    Follow Pharma Now’s social handles:

    • LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/pharma-now/?viewAsMember=true⁠⁠⁠
    • Facebook: ⁠⁠⁠https://www.facebook.com/profile.php?id=61559659700692⁠⁠⁠
    • X: ⁠⁠⁠https://x.com/PharmaNowGlobal⁠⁠⁠
    • Instagram: ⁠⁠⁠https://www.instagram.com/pharmanow.live/⁠⁠⁠

    Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.

    Show More Show Less
    6 mins
  • Can the World Stop an Ebola Outbreak That Has No Vaccine?
    Nov 17 2026

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

    In this episode of Pharma Explained, by Pharma Now, we look at an Ebola outbreak in the Democratic Republic of the Congo caused by a strain that has no approved vaccine or treatment made for it. The World Health Organization has just recommended adding two new vaccine candidates to a trial in the country, including one developed by Oxford with the Serum Institute of India. We explain how a vaccine trial works in the middle of an outbreak, why this strain is harder to fight, and what is still unknown. We also look at how cheaper malaria vaccines made in India could reach more children.

    We’ll cover:

    • Why this Ebola strain is different from the one the current vaccine targets.
    • How vaccines are tested during an outbreak.
    • What the new trials could mean for patients, and what we still don’t know.
    • Why WHO says vaccines alone will not end the outbreak.
    • How cheaper malaria vaccines could reach more children.

    For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.

    Follow Pharma Now’s social handles:

    • LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/pharma-now/?viewAsMember=true⁠⁠⁠
    • Facebook: ⁠⁠⁠https://www.facebook.com/profile.php?id=61559659700692⁠⁠⁠
    • X: ⁠⁠⁠https://x.com/PharmaNowGlobal⁠⁠⁠
    • Instagram: ⁠⁠⁠https://www.instagram.com/pharmanow.live/⁠⁠⁠

    Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.

    Show More Show Less
    7 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.